Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma
Metrics: PDF 3069 views | HTML 2611 views | ?
Yuan-Xiang Shi1,2, Tao Zhu1, Ting Zou1, Wei Zhuo1, Yi-Xin Chen1, Ma-Sha Huang1, Wei Zheng1, Chen-Jing Wang1, Xi Li1, Xiao-Yuan Mao1, Wei Zhang1, Hong-Hao Zhou1, Ji-Ye Yin1,2, Zhao-Qian Liu1,2
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China
2Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, P.R.China
Zhao-Qian Liu, email: firstname.lastname@example.org
Ji-Ye Yin, email: email@example.com
Keywords: prognosis, biomarker, lung cancer, CDK1, MAD2L1
Received: August 23, 2016 Accepted: October 28, 2016 Published: November 09, 2016
Lung cancer remains as the leading cause of cancer-related death worldwide, and lung adenocarcinoma (LUAD) is the most common histological subtype. This study aims to investigate biomarkers associated with cancer progression and prognosis of LUAD. We integrated expression profiles of 668 lung cancer patients in five datasets from the Gene Expression Omnibus (GEO) and identified a panel of differentially expressed genes (DEGs). Function enrichment analysis highlighted that these genes were closely associated with the carcinogenesis of LUAD, such as cell cycle, ECM-receptor interaction and p53 signaling pathway. Cyclin-dependent kinase 1 (CDK1) and MAD2 mitotic arrest deficient-like 1 (MAD2L1), two critical mitotic checkpoint genes, were selected for further study. Elevated expression of CDK1 and MAD2L1 was validated in an independent LUAD cohort. Kaplan-Meier analysis revealed that CDK1 and MAD2L1 expression was negatively correlated with both overall survival (OS) and relapse-free survival (RFS). In conclusion, CDK1 and MAD2L1 were adverse prognostic biomarkers for LUAD whose increased expression could render patients with LUAD a high risk of cancer recurrence and poor survival, suggesting that they might be applied as potential targets for LUAD treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.